Cardiff Oncology jumps on positive data from mid-stage studies

Cardiff Oncology

27/09/2023 14:42

** Cardiff Oncology  CRDF.O  shares rise 16.7% to $1.89 
    ** Co said on Tuesday its onvansertib therapy showed
positive results in mid-stage studies for a type of pancreatic
cancer called metastatic pancreatic ductal adenocarcinoma
(mPDAC) and small cell lung cancer (SCLC)
    ** Onvansertib shows greater efficacy for mPDAC when used in
combination with standard-of-care, which is the degree of care a
reasonable person would exercise under the circumstances - CRDF
    ** Co says the SCLC trial looked at safety data from the
first six patients using onvansertib and confirmed the trial can
continue to enroll as planned
    ** Up to last close, shares up 15.7% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))